CAR-T-Cell Therapy: Present Progress and Future strategies

被引:5
|
作者
Abbasi, Muddasir Hassan [1 ]
Riaz, Amna [1 ]
Khawar, Muhammad Babar [2 ]
Farooq, Adil [1 ]
Majid, Ayesha [1 ]
Sheikh, Nadeem [3 ]
机构
[1] Univ Okara, Dept Zool, Okara, Punjab, Pakistan
[2] Univ Narowal, Dept Zool, Appl Mol Biol & Biomed Lab, Narowal, Pakistan
[3] Univ Punjab, Inst Zool, Cell & Mol Biol Lab, Lahore, Pakistan
来源
BIOMEDICAL RESEARCH AND THERAPY | 2022年 / 9卷 / 02期
关键词
CAR-T; Immunotherapy; Malignancies; T-cell receptor; Tumor antigens; B-CELL; CHIMERIC RECEPTORS; MALIGNANCIES; CANCER; TISAGENLECLEUCEL; IMMUNOTHERAPY; INHIBITION; LYMPHOMA;
D O I
10.15419/bmrat.v9i2.726
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses the patient's immune system. It creates cancer-killing T cells through genetic modification that targets tumor antigens. CAR consists of three fundamental units, the extracellular, transmembrane, and intracellular domains. CARs are rapidly evolving with progress in the field of immunotherapy starting from first-generation CARs to next-generation CARs. Different cancer types, including B-cell malignancies, are being treated by CART therapy. The FDA has approved two CART therapies, namely, tisagenlecleucel and axicabtagene ciloleucel. The recently approved CART products are Lisocabtagene maraleucel and Idecabtagene vicleucel. Despite the success of CART therapy, several limitations, including cytokine release syndrome and neurotoxicity, need to be overcome. In the present review, we have provided an overview of CAR generations, their applications, potential limitations, and possible solutions for improving CART therapy for a variety of tumor types.
引用
收藏
页码:4920 / 4929
页数:11
相关论文
共 50 条
  • [1] T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it
    Yin, Xuechen
    He, Lingfeng
    Guo, Zhigang
    [J]. IMMUNOLOGY, 2023, 169 (04) : 400 - 411
  • [2] Current progress of CAR-T-cell therapy for patients with multiple myeloma
    Nakashima, Takahiro
    Kagoya, Yuki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 15 - 22
  • [3] A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives
    Montoya, Megan
    Gallus, Marco
    Phyu, Su
    Haegelin, Jeffrey
    de Groot, John
    Okada, Hideho
    [J]. CELLS, 2024, 13 (09)
  • [4] Dynamic imaging for CAR-T-cell therapy
    Emami-Shahri, Nia
    Papa, Sophie
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 386 - 390
  • [5] Advances in CAR-T-cell therapy in T-cell malignancies
    Zheng, Rubing
    Zhu, Xiaojian
    Xiao, Yi
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [6] outlook A solid start for CAR-T-cell therapy
    Dolgin, Elie
    [J]. NATURE, 2022, 612 (7941) : S50 - S52
  • [7] Challenges of Anti-Mesothelin CAR-T-Cell Therapy
    Zhai, Xuejia
    Mao, Ling
    Wu, Min
    Liu, Jie
    Yu, Shicang
    [J]. CANCERS, 2023, 15 (05)
  • [8] One Year Kymriah® CAR-T-Cell Therapy in Germany
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (11) : 619 - 619
  • [9] Prolonged haematologic toxicity in CAR-T-cell therapy: A review
    Liu, Qi
    Hu, Tonglin
    Li, Hangchao
    Shen, Yingying
    Wu, Dijiong
    Ye, Baodong
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (23) : 3662 - 3671
  • [10] Epigenetics Meets CAR-T-Cell Therapy to Fight Cancer
    Santourlidis, Simeon
    Arauzo-Bravo, Marcos J.
    Erichsen, Lars
    Bendhack, Marcelo L.
    [J]. CANCERS, 2024, 16 (10)